TCRX - TScan Therapeutics, Inc. Stock Price, Fair Value and News

$2.97+0.04 (+1.37%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TCRX Price Action

Last 7 days

4.2%

Last 30 days

-27.9%

Last 90 days

-46.2%

Trailing 12 Months

-40.4%

TCRX RSI Chart

TCRX Valuation

Market Cap

352.5M

Price/Earnings (Trailing)

-3.17

Price/Sales (Trailing)

37.66

Price/Free Cashflow

-3.19

TCRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TCRX Fundamentals

TCRX Revenue

Revenue (TTM)

9.4M

Rev. Growth (Yr)

-73.01%

Rev. Growth (Qtr)

95.71%

TCRX Earnings

Earnings (TTM)

-111.3M

Earnings Growth (Yr)

-29.96%

Earnings Growth (Qtr)

5.6%

TCRX Profitability

Return on Equity

-48.59%

Return on Assets

-31.98%

Free Cashflow Yield

-31.37%

TCRX Investor Care

Shares Dilution (1Y)

25.17%

Diluted EPS (TTM)

-0.74

TCRX Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	14.8M	12.2M	9.4M	0
2023	17.3M	16.4M	16.9M	21.0M
2022	11.1M	12.3M	13.3M	13.5M
2021	3.3M	5.6M	7.9M	10.1M
2020	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

CEO	Dr. Gavin MacBeath Ph.D.
WEBSITE	tscan.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	135

TScan Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for TScan Therapeutics, Inc.? What does TCRX stand for in stocks?

TCRX is the stock ticker symbol of TScan Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TScan Therapeutics, Inc. (TCRX)?

As of Fri Dec 20 2024, market cap of TScan Therapeutics, Inc. is 352.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TCRX stock?

You can check TCRX's fair value in chart for subscribers.

Is TScan Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TCRX is over valued or under valued. Whether TScan Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact TScan Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TCRX.

What is TScan Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, TCRX's PE ratio (Price to Earnings) is -3.17 and Price to Sales (PS) ratio is 37.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TCRX PE ratio will change depending on the future growth rate expectations of investors.